Biotechnology: Delivering on the promise

Science Translational Medicine

Volumn 2, Issue 13, 2010, Pages

  Greenwood, James C ^a  

^a Biotechnology Industry Organization   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGICAL PRODUCTION; BIOTECHNOLOGY; CLINICAL RESEARCH; DRUG APPROVAL; DRUG COST; DRUG RESEARCH; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HUMAN; NOTE; PATIENT SAFETY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROGRAM DEVELOPMENT; REIMBURSEMENT;

BIOMEDICAL RESEARCH; BIOTECHNOLOGY; DRUG INDUSTRY; HUMANS; PUBLIC POLICY; RESEARCH; RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 77953000489     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000357     Document Type: Note

References (13)

1. D. Strickland, Ed., Guide to Biotechnology 2007 (BIO, Washington, DC, 2007).
2. 2008 Report Medicines in Development: Biotechnology (Pharmaceutical Research and Manufacturers of America, Washington, DC, 2008).
3. J. DiMasi, H. Grabowski, The cost of biopharmaceutical R&D: Is biotech different? Manage. Decis. Econ. 28, 469-479 (2007).
4. BIO, unpublished data analysis.
5. BIO, unpublished analysis of data from FactSet Research Systems, Inc. database.
6. BIO and Thompson Reuters, The Outlook and Issues for the Biotechnology Sector: An Investor Perception Study (2009); (http://www.bio.org/edocs/BIO- ThomsonReuters09-study.pdf).
7. National Health Expenditures Aggregate Amounts and Average Annual Percent Change, by Type of Expenditure: Selected Calendar Years 1960-2007 (Centers for Medicare & Medicaid Services, Office of the Actuary, National Health Statistics Group, Washington, DC, 2008).
8. Technological Change and the Growth in Health Care Spending (U.S. Congressional Budget Office, Washington, DC, 2008).
9. K. Thorpe, The rise in health care spending and what to do about it. Health Aff. 24, 1436-1445 (2005).
10. C. Clift, The value of patent term extensions to the pharmaceutical industry in the USA. J. Gene Med. 5, 201-208 (2008).
11. H. Grabowski, M. Kyle, Generic competition and market exclusivity periods in pharmaceuticals. Manage. Decis. Econ. 28, 491-502 (2007).
12. H. Grabowski, Follow-on biologics: Data exclusivity and the balance between innovation and competition. Nat. Rev. Drug Discov. 7, 479-488 (2008).
13. H.R. 3590, Patient Protection and Aff ordable Care Act (Amendment in Senate), Section 9023.